Compare iShares Core High Dividend ETF (HDV) vs Philip Morris International Inc. (PM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core High Dividend ETF vs Philip Morris International Inc. — how do they compare? iShares Core High Dividend ETF trades at $28.78 (market cap $14.72B), while Philip Morris International Inc. trades at $200.2 (market cap $300.33B). The key difference: Philip Morris International Inc. is far larger — about 20.4× iShares Core High Dividend ETF's market cap, and Philip Morris International Inc. pays a 3.32% dividend while iShares Core High Dividend ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares Core High Dividend ETF for 117 Days and Philip Morris International Inc. for 85 Days on average.
| HDV | PM | |
|---|---|---|
Market Cap | $14.72B | $300.33B |
Volume | 2,297,177 | 3,935,700 |
52-Week High | $29.93 | $200.50 |
52-Week Low | $23.64 | $144.33 |
Typical Hold Time | 117 Days | 85 Days |
Sector | — | Consumer Staples |
Enterprise Value | — | $343.44B |
Dividend Yield | — | 3.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HDV (iShares Core High Dividend ETF) trades at $28.28, down 0.28% with neutral technical signals. The ETF recently underwent significant sector rebalancing, reducing healthcare exposure by nearly half while increasing energy, staples, and utilities. Technical indicators show mixed signals with bearish moving averages but neutral oscillators. Recent dividend payments of $0.06-$0.10 per share demonstrate consistent income generation, though the fund's 3% yield may not fully compensate for increased concentration risks.
The outlook remains cautious as HDV's sector concentration (62% in three sectors) creates heightened risk exposure. While the dividend yield provides income stability, the fund's recent underperformance relative to peers and reduced diversification warrant careful monitoring. Investors should weigh the trade-off between current income and long-term growth potential given the significant portfolio restructuring.
Philip Morris International (PM) trades at $200.5, up 5.3% over 24 hours, with a bullish technical signal and strong earnings beats in Q1 and Q2 2026. The company shows robust fundamentals with 2025 revenue of $40.65B and net income of $11.35B, supported by a 67.48% gross margin. Recent news highlights expansion of smoke-free products like ZYN and IQOS, now over 40% of revenue, driving growth amid industry shifts.
Outlook is positive with analyst consensus at Buy (68%) and a $212.17 price target, though elevated P/E of 26.46 and regulatory risks in tobacco remain concerns. Earnings growth and smoke-free product adoption are key catalysts, but investors should monitor debt levels and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Core High Dividend ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The underlying index is comprised of qualified income paying securities that are screened for superior company quality and financial health as determined by Morningstar, Inc.'s proprietary index methodology. The fund is non-diversified.
Read more on HDV →About Philip Morris International Inc.
Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.
Read more on PM →
